Role of proteoglycans and glycosaminoglycans in Duchenne muscular dystrophy
- 19 June 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 29 (2) , 110-123
Abstract
Duchenne muscular dystrophy (DMD) is an inherited fatal X-linked myogenic disorder with a prevalence of 1 in 3500 male live births. It affects voluntary muscles, and heart and breathing muscles. DMD is characterized by continuous degeneration and regeneration cycles resulting in extensive fibrosis and a progressive reduction in muscle mass. Since the identification of a reduction in dystrophin protein as the cause of this disorder, numerous innovative and experimental therapies, focusing on increasing the levels of dystrophin, have been proposed, but the clinical improvement has been unsatisfactory. Dystrophin forms the dystrophin-associated glycoprotein complex and its proteins have been studied as a promising novel therapeutic target to treat DMD. Among these proteins, cell surface glycosaminoglycans (GAGs) are found almost ubiquitously on the surface and in the extracellular matrix (ECM) of mammalian cells. These macromolecules interact with numerous ligands, including ECM constituents, adhesion molecules and growth factors that play a crucial role in muscle development and maintenance. In this article, we have reviewed in vitro, in vivo and clinical studies focused on the functional role of GAGs in the pathophysiology of DMD with the final aim of summarizing the state of the art of GAG dysregulation within the ECM in DMD and discussing future therapeutic perspectives.Keywords
This publication has 100 references indexed in Scilit:
- Iduronic Acid in Chondroitin/Dermatan Sulfate Affects Directional Migration of Aortic Smooth Muscle CellsPLOS ONE, 2013
- Biochemical and mechanical environment cooperatively regulate skeletal muscle regenerationThe FASEB Journal, 2012
- Biglycan Is an Extracellular MuSK Binding Protein Important for Synapse StabilityJournal of Neuroscience, 2012
- Restoring Dystrophin Expression in Duchenne Muscular Dystrophy MuscleThe American Journal of Pathology, 2011
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences, 2010
- Antibody GD3G7 Selected against Embryonic Glycosaminoglycans Defines Chondroitin Sulfate-E Domains Highly Up-Regulated in Ovarian Cancer and Involved in Vascular Endothelial Growth Factor BindingThe American Journal of Pathology, 2007
- Biglycan binds to α‐ and γ‐sarcoglycan and regulates their expression during developmentJournal of Cellular Physiology, 2006
- Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOSThe FASEB Journal, 2006
- Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophagesClinical and Experimental Immunology, 2006
- The effect of hyaluronan on osteoblast proliferation and differentiation in rat calvarial‐derived cell culturesJournal of Biomedical Materials Research Part A, 2003